Bridge Biotherapeutics signs joint research accords with US schools on cancer immunotherapy
Bridge Biotherapeutics said Wednesday it has signed collaborative research agreements with the University of Colorado and Emory University to explore the potential for expanding the indications of BBT-877, an autotaxin inhibitor, as an immuno-oncology …